• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

在连续使用利妥昔单抗治疗后，出现与原发性皮肤弥漫性大B细胞淋巴瘤（腿部型）肿瘤病变相对应的短暂性风团发作。

Transient wheal attack corresponding to the tumor lesions of primary cutaneous diffuse large B cell lymphoma, leg type after successive rituximab treatment.

作者信息

Itoi Saori, Tanemura Atsushi, Hayashi Misa, Nagata Naoko, Tani Mamori, Katayama Ichiro

机构信息

Division of Dermatology, Department of Integrated Medicine, Osaka University Graduate School of Medicine, Osaka, Japan.

出版信息

Case Rep Dermatol. 2014 Sep 11;6(3):218-21. doi: 10.1159/000367936. eCollection 2014 Sep.

DOI:10.1159/000367936
PMID:25408649
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4209260/
Abstract

An elderly male noticed urticarial patches corresponding to cutaneous B cell lymphoma lesions after rituximab treatment. Along with the resolution of urticaria, the lymphoma lesions completely remitted without recurrence. In this communication, we present an interesting case and the pathophysiological findings of a wheal attack in a case with tumor remission following systemic treatment with rituximab, a monoclonal anti-CD20 antibody.

摘要

一位老年男性在接受利妥昔单抗治疗后，出现了与皮肤B细胞淋巴瘤病变相对应的荨麻疹斑块。随着荨麻疹的消退，淋巴瘤病变完全缓解且未复发。在本报告中，我们呈现了一个有趣的病例，以及一例在用单克隆抗CD20抗体利妥昔单抗进行全身治疗后肿瘤缓解的病例中，风团发作的病理生理结果。

相似文献

1
Transient wheal attack corresponding to the tumor lesions of primary cutaneous diffuse large B cell lymphoma, leg type after successive rituximab treatment.在连续使用利妥昔单抗治疗后，出现与原发性皮肤弥漫性大B细胞淋巴瘤（腿部型）肿瘤病变相对应的短暂性风团发作。
Case Rep Dermatol. 2014 Sep 11;6(3):218-21. doi: 10.1159/000367936. eCollection 2014 Sep.
2
Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the CD20-antibody rituximab.采用CD20抗体利妥昔单抗一线单药治疗使一例小腿原发性皮肤B细胞淋巴瘤完全缓解。
J Cancer Res Clin Oncol. 2002 Mar;128(3):161-6. doi: 10.1007/s00432-001-0313-2. Epub 2002 Jan 25.
3
Primary cutaneous large B-cell lymphoma of the legs: a distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab).腿部原发性皮肤大B细胞淋巴瘤：一种采用CD20单克隆抗体（利妥昔单抗）治疗的独特临床病理实体。
Am J Clin Oncol. 2001 Jun;24(3):237-40. doi: 10.1097/00000421-200106000-00005.
4
Rituximab in cutaneous B-cell lymphoma: a report of two cases.利妥昔单抗治疗皮肤B细胞淋巴瘤：两例报告
Br J Dermatol. 2000 Jul;143(1):157-61. doi: 10.1046/j.1365-2133.2000.03607.x.
5
[Relapse of diffuse large B cell lymphoma to CD20-negative multiple cutaneous tumors immediately after anti-CD20 monoclonal antibody (rituximab) therapy].[弥漫性大B细胞淋巴瘤在抗CD20单克隆抗体（利妥昔单抗）治疗后立即复发为CD20阴性的多发性皮肤肿瘤]
Rinsho Ketsueki. 2004 Oct;45(10):1129-34.
6
Spontaneous regression of primary cutaneous diffuse large B-cell lymphoma, leg type with significant T-cell immune response.原发性皮肤弥漫性大B细胞淋巴瘤，腿部型伴显著T细胞免疫反应的自发消退
JAAD Case Rep. 2018 Mar 31;4(4):305-309. doi: 10.1016/j.jdcr.2017.10.012. eCollection 2018 May.
7
Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.抗CD20抗体（利妥昔单抗）全身治疗对原发性皮肤B细胞淋巴瘤患者肿瘤负荷的降低及疾病的稳定作用。
Cancer. 2000 Oct 15;89(8):1835-44.
8
Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas--an applicational observation.原发性皮肤B细胞淋巴瘤的全身性八周期抗CD20单克隆抗体（利妥昔单抗）治疗——一项应用观察
Br J Dermatol. 2005 Jul;153(1):167-73. doi: 10.1111/j.1365-2133.2005.06659.x.
9
Long-term outcome of intravenous therapy with rituximab in patients with primary cutaneous B-cell lymphomas.原发性皮肤 B 细胞淋巴瘤患者静脉注射利妥昔单抗的长期疗效。
Br J Dermatol. 2013 Nov;169(5):1126-32. doi: 10.1111/bjd.12484.
10
Rituximab in the treatment of primary cutaneous B-cell lymphoma: a review.利妥昔单抗治疗原发性皮肤B细胞淋巴瘤：综述
Actas Dermosifiliogr. 2014 Jun;105(5):438-45. doi: 10.1016/j.ad.2012.10.021. Epub 2013 Mar 26.

引用本文的文献

1
Primary cutaneous diffuse large B-cell lymphoma after total knee arthroplasty: a case study and a systematic review of its cutaneous manifestations and treatment options.全膝关节置换术后原发性皮肤弥漫性大B细胞淋巴瘤：一例病例研究及其皮肤表现和治疗选择的系统综述
Postepy Dermatol Alergol. 2022 Jun;39(3):545-552. doi: 10.5114/ada.2021.108444. Epub 2021 Aug 16.

本文引用的文献

1
Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses.利妥昔单抗相关的荨麻疹反应叠加于原发性皮肤滤泡中心淋巴瘤：组织学表现及病理生理假说
J Eur Acad Dermatol Venereol. 2014 Jul;28(7):976-8. doi: 10.1111/jdv.12313. Epub 2013 Nov 9.
2
Understanding rituximab function and resistance: implications for tailored therapy.理解利妥昔单抗的作用和耐药性：对个体化治疗的启示。
Front Biosci (Landmark Ed). 2011 Jan 1;16(2):770-82. doi: 10.2741/3719.
3
Rituximab: mechanism of action.
利妥昔单抗：作用机制。
Semin Hematol. 2010 Apr;47(2):115-23. doi: 10.1053/j.seminhematol.2010.01.011.
4
A case of rituximab-related urticarial reaction in cutaneous B-cell lymphoma.1例皮肤B细胞淋巴瘤中与利妥昔单抗相关的荨麻疹反应
J Eur Acad Dermatol Venereol. 2009 Feb;23(2):210. doi: 10.1111/j.1468-3083.2008.02792.x. Epub 2008 May 12.
5
Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.一名接受原发性皮肤B细胞淋巴瘤治疗的患者发生了与利妥昔单抗相关的荨麻疹反应。
Ann Oncol. 2006 Nov;17(11):1720-1. doi: 10.1093/annonc/mdl113. Epub 2006 May 26.
6
Complement activation plays a key role in the side-effects of rituximab treatment.补体激活在利妥昔单抗治疗的副作用中起关键作用。
Br J Haematol. 2001 Dec;115(4):807-11. doi: 10.1046/j.1365-2141.2001.03166.x.
7
Rituximab therapy of B-cell neoplasms.利妥昔单抗治疗B细胞肿瘤
Clin Lymphoma. 2000 Dec;1(3):186-94; discussion 195-6. doi: 10.3816/clm.2000.n.015.
8
Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma.抗CD20抗体（利妥昔单抗）全身治疗对原发性皮肤B细胞淋巴瘤患者肿瘤负荷的降低及疾病的稳定作用。
Cancer. 2000 Oct 15;89(8):1835-44.
9
Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs.嵌合抗CD20（IDEC-C2B8）单克隆抗体使一种B细胞淋巴瘤细胞系对细胞毒性药物的细胞杀伤作用敏感。
Cancer Biother Radiopharm. 1997 Jun;12(3):177-86. doi: 10.1089/cbr.1997.12.177.
10
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20.通过一种针对CD20的嵌合小鼠人单克隆抗体在体内耗尽B细胞。
Blood. 1994 Jan 15;83(2):435-45.